Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma

Li Jung Ma, Sung Wei Lee, Li Ching Lin, Tzu Ju Chen, I. Wei Chang, Han Ping Hsu, Kwang Yu Chang, Hsuan Ying Huang, Chien Feng Li

研究成果: 雜誌貢獻文章同行評審

26 引文 斯高帕斯(Scopus)

摘要

Despite recent improvements in the diagnosis and treatment, the final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database with further bioinformatic validation, fibronectin (FN1) was identified as a differentially upregulated gene in NPC tissues, which implicates the transition from epithelial to mesenchymal phenotype (EMT) and promotes metastasis. Given the roles of fibronectin in risk stratification and in the frontline therapeutics of common carcinomas, such as renal cell cancer, we explored fibronectin immunoexpression status and its associations with clinicopathological variables and survival in a well-defined cohort of NPC patients. Fibronectin immunohistochemistry was retrospectively performed and analyzed using H-score for 124 biopsy specimens from NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score higher than the median value were regarded as fibronectin overexpression. The findings were correlated with clinicopathological variables, EBV latent membrane protein 1 (LMP1) expression, disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Fibronectin overexpression was significantly associated with American Joint Committee on Cancer (AJCC) stages III-IV (p=0.019) and LMP1 expression (p=0.004), and univariately predictive of adverse outcomes for DSS, DMFS, and LRFS (all p<0.0001). In the multivariate comparison, fibronectin overexpression still remained prognostically independent to portend worse DSS (p<0.01, hazard ratio=5.958), DMFS (p<0.01, hazard ratio=5.728), and LRFS (p<0.01, hazard ratio=5.411) together with advanced AJCC stages III-IV. Fibronectin is upregulated in a subset of NPCs, and its increased immunoexpression significantly correlated with advanced features, justifying the potentiality of fibronectin as a theragnostic biomaker of NPC.
原文英語
頁(從 - 到)1703-1712
頁數10
期刊Tumor Biology
35
發行號2
DOIs
出版狀態已發佈 - 一月 1 2014
對外發佈Yes

ASJC Scopus subject areas

  • Cancer Research

指紋 深入研究「Fibronectin overexpression is associated with latentmembrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma」主題。共同形成了獨特的指紋。

引用此